دانلود مقاله با موضوع انتقال سریع به اومالیزوماب خانگی درمان کهیر خودبخودی مزمن در طول همه گیری COVID-19
در قالب pdf و در 6 اسلاید،قابل ویرایش، شامل:
موضوع به انگلیسی:Rapid transition to home omalizumab
treatment for chronic spontaneous urticaria
during the COVID-19 pandemic
بخشی از متن:Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the
focus of much attention from healthcare professionals worldwide. In Ireland, due to funding
constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with
chronic spontaneous urticaria and angioedema (CSU) receiving omalizumab in our centre were
rapidly transitioned to home self-administration at the start of the pandemic. We conducted an
anonymised patient survey after 3 months of home therapy with the aim of characterizing the
patient experience throughout this period. 41 patients participated in our questionnaire (71%
response rate). 93% of patients favored self-injection of omalizumab from home, with respondents
citing cost savings, time savings, improved flexibility, fewer hospital visits, and less risk of exposure
to COVID-19 infection as particular benefits. Concerns regarding home administration including
injecting incorrectly, forgetting a dose, or having a reaction were reported very infrequently.
Eighty-three percent (83%) of patients wished to continue with home therapy long-term. This
survey highlights broadly positive experiences for patients rapidly transitioning to home omalizumab
administration. This data will be useful to inform healthcare funders in decisions regarding
patient-centred care in CSU. Facilitating home omalizumab therapy in suitable CSU patients
should be strongly considered in the post-pandemic setting.
Keywords: Chronic urticaria, Omalizumab, Self-administration, Patient reported outcome measure,
COVID-19
